Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (PSTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pstx · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Poseida Therapeutics, Inc. (PSTX) measures how much investors pay for each dollar of the company's trailing earnings. PSTX's current PE ratio of N/A is calculated by dividing its stock price of $9.50 by its TTM earnings per share of -$1.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2016 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Poseida Therapeutics, Inc.You PSTX | $926M | N/A | — | -$1.37 |
 Albireo Pharma, Inc. ALBO | $916M | N/A | — | -$7.87 |
 Crescent Biopharma, Inc. CBIO | $476M | N/A | — | -$14.78 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Gracell Biotechnologies Inc. GRCL | $198M | N/A | — | -$44.87 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-1.37 | — | |
2022-12-31 FY2022 | — | $-0.89 | — | |
2021-12-31 FY2021 | 96.15x | $0.07 | -63.2% | |
2020-12-31 FY2020 | 261.23x | $0.04 | — | |
2019-12-31 FY2019 | — | $-2.33 | — | |
2018-12-31 FY2018 | — | $-1.24 | — | |
2017-12-31 FY2017 | — | $-0.49 | — | |
2016-12-31 FY2016 | — | $-0.08 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Poseida Therapeutics, Inc. (PSTX) measures how much investors pay for each dollar of the company's trailing earnings. PSTX's current PE ratio of N/A is calculated by dividing its stock price of $9.50 by its TTM earnings per share of -$1.37.
Frequently asked questions
PSTX pe ratio · 6 questionsPSTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $9.50 and TTM EPS of -$1.37. Data sourced from Financial Modeling Prep via PSTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Poseida Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09